Introduction {#s1}
============

The term "Lewy body disorders (LBD)" subsumes the three entities Parkinson's disease (PD) without dementia (PDND), PD with dementia (PDD), and dementia with Lewy bodies (DLB) [@pone.0048042-Lippa1]. In LBD, alpha-synuclein (Asyn)-positive Lewy bodies (LB) and Lewy neurites occur together with neurodegeneration [@pone.0048042-Buchman1].

Moreover, co-occurrence of amyloid-beta (Abeta) deposits with Asyn pathology is common, particularly in LBD patients with dementia [@pone.0048042-Braak1], [@pone.0048042-Maetzler1]. It is widely accepted that an Abeta~1--42~ production higher than its removal results in an enhanced presence of Abeta~1--42~ monomers, oligomers, insoluble fibrils and plaques in the central nervous system [@pone.0048042-Mawuenyega1]. Age, *ApoE* genotype [@pone.0048042-Pankratz1] as well as proteins and metabolites such as apolipoprotein E [@pone.0048042-Strittmatter1], apolipoprotein J (clusterin) [@pone.0048042-Ghiso1], apolipoprotein A1 [@pone.0048042-Roher1], uric acid [@pone.0048042-Maetzler2], neprilysin [@pone.0048042-Maetzler3], tau proteins [@pone.0048042-Arai1], cystatin C [@pone.0048042-Maetzler4], and transthyretin [@pone.0048042-Li1], [@pone.0048042-Schwarzman1] play a role in the neurotoxic aggregation of the usually soluble form of Abeta~1--42~. Similar mechanisms may lead to Asyn accumulation, at least for late onset PD although there is less evidence for this hypothesis [@pone.0048042-Deleidi1].

The *transthyretin (TTR)* gene is located at chromosome 18q11 and consists of four exons [@pone.0048042-Tsuzuki1]. TTR is mainly synthesized in the liver and the epithelial cells of the choroid plexus [@pone.0048042-Schreiber1]. Recent results indicate that it is also a neuronal product up-regulated in Alzheimer's disease (AD) [@pone.0048042-Li2]. It has binding sites for retinol binding protein (RBP), thyroxin and also for Abeta~1--42~ [@pone.0048042-Du1]. It can influence Abeta~1--42~ aggregation and destroy already formed Abeta~1--42~ fibrils by proteolytic cleavage of the peptides [@pone.0048042-Costa1]. It has been suggested that TTR may be one of the major Abeta~1--42~-binding and -sequestering proteins in human cerebrospinal fluid (CSF) [@pone.0048042-Li1], [@pone.0048042-Schwarzman1]. Increased production of TTR in neurons exposed to Abeta~1--42~ toxicity, and reduced levels of the protein in blood [@pone.0048042-Velayudhan1], [@pone.0048042-Han1] and CSF [@pone.0048042-Gloeckner1]--[@pone.0048042-Hansson1] indicate an involvement of TTR (dys)function in clearance deficits as they occur in AD. In addition, there is very recent - at least indirect - evidence that TTR may be involved in Asyn clearance. Guerreiro and colleagues [@pone.0048042-Guerreiro1] observed highly increased levels of monomeric and oligomerized Asyn in the saliva of symptomatic heterozygous V30M *TTR* mutation carriers suffering from familial amyloidosis compared to healthy control individuals. Interestingly, Asyn levels in saliva of symptomatic *TTR* mutation carriers who underwent orthotropic liver transplantation (and, consecutively, had non-mutated *TTR*) were comparable with those of controls.

It has been demonstrated that not only the relatively rare mutations but also common variants of the *TTR* gene are differentially capable of altering the ability of TTR to carry and transport its ligands [@pone.0048042-Ruano1]. This has been shown in particular for the *TTR* single nucleotide polymorphisms (SNPs) rs13381522 and rs3764478 (both lie at the 5\`end in the promoter region of the *TTR* gene), rs1800458 (located in exon 2, leads to a non-synonymous amino acid exchange of glycin to serin on position 26 of the *TTR* nucleotide sequence), rs723744 (localized in intron 3, does not result in amino acid differences), and rs36204272 (is intronic and spliced posttranslationally, should have no effect on the TTR protein) [@pone.0048042-Schwarzman1], [@pone.0048042-Cuenco1]--[@pone.0048042-Olsson1]. As LBD patients obviously show neuronal and neural clearance deficits comparable to AD [@pone.0048042-Deleidi1] and TTR seems to be critically involved in these mechanisms, we hypothesized that blood and CSF levels of TTR are altered in LBD patients and may be associated with clinical and demographic data, and that occurrence of the abovementioned SNPs are associated with these TTR levels.

Study Participants, Material and Methods {#s2}
========================================

Ethics Statement {#s2a}
----------------

The study was approved by the ethics committee of the Medical Faculty, University of Tuebingen, Germany, and was performed according to the principles expressed in the Declaration of Helsinki. All participants gave their written informed consent. In case of compromised capacity of the participants to consent (MMSE \<18 points), or another person was named to make decisions on behalf of the person, responsible persons consented on the behalf of the participant.

Study Participants {#s2b}
------------------

Demented DLB, PDD and non-demented LBD patients (PDND), and elderly neurodegeneratively healthy control individuals (HC) were recruited from the ward and the outpatient clinic of the Neurodegenerative Department of the University of Tuebingen. LBD patients were diagnosed based on clinical criteria by specialists in the field of neurodegenerative movement disorders (DB, TG, WM). All PD patients fulfilled the UKPDS Brain Bank criteria [@pone.0048042-Gibb1]. PDD patients, in addition, met the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria for dementia as well as core and associated clinical features proposed by Emre and colleagues [@pone.0048042-Emre1]. All DLB patients fulfilled the McKeith criteria for clinical diagnosis of probable DLB [@pone.0048042-McKeith1]. Control individuals underwent spinal taps for exclusion of vascular events or inflammatory conditions. Any clinical sign for a neurodegenerative disorder led to exclusion from the study.

All individuals underwent demographic analysis and clinical testing including a Hoehn&Yahr (H&Y) staging and a Mini-Mental State Examination (MMSE). [Table 1](#pone-0048042-t001){ref-type="table"} provides an overview of demographic, clinical, and biochemical data of the groups.
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###### Demographic, clinical, and routine biochemical data.

![](pone.0048042.t001){#pone-0048042-t001-1}

                                               LBD                Controls            *p*-value                       
  ----------------------------------- --------------------- --------------------- ----------------- ----------------- -------------
  Individuals (f/m) \[n\]                **131 (59/72)**       **72 (34/38)**           0.88                          
                                           77 (34/43)            26 (11/15)          28 (14/14)                       
  Age \[years\]: all                     **70 (44--84)**       **57 (40--80)**         \<.0001                        
                                           68 (44--81)           71 (62--84)         74 (50--83)                      
  females                                                      **70 (44--84)**                       **57 (43--79)**   **\<.0001**
                                           68 (44--80)           71 (64--84)         76 (50--83)                      
  males                                                        **69 (46--84)**                       **58 (40--80)**     \<.0001
                                           68 (46--81)           71 (62--84)         71 (58--78)                      
  Aao parkinsonism \[years\]             **63 (30--79)**                                                              
                                           62 (30--79)           63 (51--74)         70 (49--78)                      
  Duration of parkinsonism\[years\]    **4.6 (0.1--25.0)**                                                            
                                         4.1 (0.1--25.0)       8.7 (3.7--21.4)     2.9 (0.9--13.2)                    
  Aao dementia \[years\]                 **69 (49--79)**                                                              
                                                                 69 (58--79)         70 (49--79)                      
  Duration dementia \[years\]          **2.8 (0.4--12.2)**                                                            
                                                               2.1 (0.4--5.9)      3.4 (0.5--12.2)                    
  H&Y stage (1--5) \[n\]               **2.5 (1.0--4.5 )**                                                            
                                            2 (1--4)              3 (2--5)            3 (1--4)                        
  MMSE (0--30)                           **27 (10--30)**       **30 (27--30)**         \<.0001                        
                                           29 (25--30)           21 (13--29)         19 (10--27)                      
  *ApoE4* \[%\]                              **34**                **15**               0.047                         
                                               33                    23                  45                           
  CSF amyloid-beta~1--42~ \[pg/ml\]    **595 (134--1458)**   **907 (264--1446)**       \<.0001                        
                                         629 (134--1458)       497 (147--851)      453 (228--1241)                    
  CSF total tau \[pg/ml\]              **199 (25--1074)**     **183 (32--868)**         0.56                          
                                         176 (25--1074)         254 (48--660)       236 (77--596)                     
  CSF phospho-tau \[pg/ml\]             **40 (12--127)**      **39 (14--158)**          0.39                          
                                          36 (15--127)          57 (12--109)         50 (22--86)                      

Demographic, clinical, and biochemical data of patients with Lewy body disorders (LBD) and controls, presented with median (range). *P*-values were determined using the Wilcoxon rank sum test, or the Fisher's exact test. Aao, age at onset; *ApoE4, Apolipoprotein E4*; CSF, cerebrospinal fluid; DLB, dementia with Lewy bodies; f, female; H&Y, Hoehn&Yahr stage; m, male; MMSE, Mini-Mental State Examination; PDD, Parkinson's disease with dementia; PDND, Parkinson's disease non-demented.

Cerebrospinal Fluid and Serum Collection {#s2c}
----------------------------------------

CSF and serum collection as well as determination of routine diagnostic parameters were performed according to standardized protocols (for details see [@pone.0048042-Maetzler5]). We only used samples specifically dedicated to this project from our biobank (<http://www.hih-tuebingen.de/de/nd/biobank/for-researchers/>), without any previous freeze-thaw cycle. Our biobank fulfills highest international standards with regard to collection, preparation and storage of biosamples. Samples for determination of TTR levels were centrifuged (CSF: 4000 g, 4°C, 10 min; blood: 2000 g, 4°C, 10 min) and stored at −80°C within 60 minutes after collection until analysis. Only samples of patients with normal routine CSF diagnostics were included in the study, slightly increased CSF albumin levels (up to 450 mg/L) were tolerated.

TTR, Abeta~1--42~, Total Tau and Phospho-tau Measurement {#s2d}
--------------------------------------------------------

TTR levels in CSF and serum were measured using a laser nephelometric method with Ics Pab Prealbumin Reagent Test Kit on Beckman Coulter IMMAGE® Immunochemistry Systems according to manufacturer's instructions (Beckman Coulter GmbH, Krefeld, Germany). Samples were run in triplicate. We observed within run precision of \<2.0% coefficient of variation (CV), and total precision of \<5% CV.

CSF Abeta~1--42~, total tau and phospho-tau levels were determined using commercially available ELISA kits (Innogenetics NV, Ghent, Belgium).

TTR and ApoE Genotyping {#s2e}
-----------------------

Genomic DNA was extracted using standard protocols. The coding sequence of the *TTR* gene was determined with Sanger-sequencing technique to identify the SNPs rs1800458 and rs36204272. SNPs rs13381522, rs3764478, and rs723744 which are located at the *TTR* intron or promoter region were analyzed by the SNaPshot method. Briefly, a PCR with specific SNaPshot primers was performed. After single base extension with fluorescent-labeled ddNTPs the SNaPshot product was analyzed by capillary gel electrophoresis with ABI Prism 3100 Genetic Analyzer sequencer (Applied Biosystems Life Technologies GmbH, Darmstadt, Germany). Fluorescence data were analyzed using Gene Mapper v3.5.

*ApoE* genotypes were obtained by PCR amplification of exon 4 of the *ApoE* gene, and subsequent digestion with enzyme HhaI according to [@pone.0048042-Hixson1]. All SNPs investigated were in Hardy-Weinberg equilibrium.

Data Analysis {#s2f}
-------------

Data were analyzed with JMP software (version 9.0.2, SAS). As dementia associated with LBD may per se be a relevant factor associated with TTR levels, PDD and DLB were not only considered as single groups but also comprised as a PDD/DLB group (see [Table S1](#pone.0048042.s001){ref-type="supplementary-material"} for details). Demographic and clinical data were analyzed with the Wilcoxon signed rank test (LBD versus controls; presented as median and range) or Fishers exact test. As age was significantly different between LBD and controls and as there is some evidence that serum TTR may be associated with age [@pone.0048042-Ritchie1], we corrected both serum and CSF TTR levels for this covariate using a regression model. The coefficient of determination (r^2^) was used as a measure for the proportion of response variation which was explained by the regressors in the model. Significance of each model effect was assessed by the likelihood ratio.

Differences were considered significant at *p*\<0.05. Post-hoc analyses (TTR levels of PDND versus controls, PDND versus demented LBD, controls versus demented LBD) were corrected for multiple testing (see [Table 2](#pone-0048042-t002){ref-type="table"} and [Table S1](#pone.0048042.s001){ref-type="supplementary-material"} for details).

10.1371/journal.pone.0048042.t002

###### Transthyretin values of the investigated cohorts.

![](pone.0048042.t002){#pone-0048042-t002-2}

                                  LBD                  Controls                *p*-value                               
  --------------------- ----------------------- ----------------------- ----------------------- ------------------- -- --
  CSF TTR \[mg/dl\]      **1.73 (0.58--2.84)**   **1.58 (0.58--2.61)**           0.037                                 
                         1.80 (0.58--2.32) ^§^     1.60 (0.58--2.84)       1.68 (0.58--2.68)                           
  Serum TTR \[mg/dl\]           females          **25.3 (12.1--39.8)**   **27.3 (19.6--48.1)**         0.39            
                                                   26.7 (16.1--39.8)       21.9 (15.5--30.1)     20.8 (12.1--31.7)     
                                 males           **29.7 (15.2--46.5)**   **31.3 (19.9--43.9)**         0.54            
                                                   31.2 (17.0--46.5)       25.6 (15.2--35.1)     30.9 (21.7--37.1)     

Transthyretin (TTR) levels were calculated using a regression model with age as a covariate. As serum TTR levels were significantly different between females and males (see text) these values were calculated separately. *P*-values \<0.05 between patients with Lewy body disorders (LBD) and controls were considered significant. Post-hoc analyses were performed for comparison of TTR levels between the following cohorts: Parkinson's disease non-demented (PDND), Parkinson's disease with dementia (PDD), dementia with Lewy bodies (DLB), controls, PDD versus DLB, PDD versus controls, and DLB versus controls, with *p-*values \<0.01 (0.05/5 groups) considered significant. CSF, cerebrospinal fluid.

Results {#s3}
=======

TTR Levels and Demographic Variables {#s3a}
------------------------------------

TTR values in CSF and serum were normally distributed, and did not correlate. They were not age-related, neither in CSF (controls, r^2^ = 0.02, *p* = 0.88; LBD patients, r^2^ = 0.01, *p* = 0.64) nor in serum (controls, r^2^ = 0.01, *p* = 0.19; LBD patients, r^2^ = 0.02, *p* = 0.11). CSF TTR values were approx. 18-fold lower than serum values (1.7 versus 30.1 mg/dl).

Gender did not differ significantly between LBD patients and controls. CSF TTR values were comparable between females and males (controls, *p* = 0.56; LBD patients, *p* = 0.59). Serum TTR levels were significantly higher in males than in females (controls, *p* = 0.03; LBD patients, *p* = 0.002) and were therefore calculated separately.

TTR Levels and LBD-associated Parameters {#s3b}
----------------------------------------

An overview is given in [Table 2](#pone-0048042-t002){ref-type="table"}. CSF TTR values were significantly higher in LBD patients (1.73 mg/dl) compared to controls (1.58 mg/dl). The post-hoc analysis demonstrated that, within the LBD group, PDND patients accounted for this effect (1.80 mg/dl, r^2^ = 0.07, p = 0.008 compared to controls). Serum TTR levels were not significantly different between LBD patients and controls, and among LBD patients (see also [Table S1](#pone.0048042.s001){ref-type="supplementary-material"}).

CSF and serum TTR values were neither significantly associated with clinical parameters (age at onset of parkinsonism, duration of parkinsonism, Hoehn&Yahr stage, age at onset of dementia, duration of dementia, MMSE score), nor with *ApoE* status.

TTR Levels and Neurodegenerative Markers {#s3c}
----------------------------------------

There were weak but significant negative correlations between CSF TTR values and respective levels of CSF Abeta~1--42~ (r^2^ = 0.03, *p* = 0.02), CSF total tau (r^2^ = 0.03, *p* = 0.02) and CSF phospho-tau (r^2^ = 0.03, *p* = 0.03). No significant correlations were detectable between serum TTR values and neurodegenerative markers.

TTR Genotypes {#s3d}
-------------

None of the analyzed *TTR* SNPs (rs723744, rs13381522, rs3764478, rs1800458 and rs36204272) showed a significant association with LBD occurrence. In addition, no relevant associations of the SNPs with demographical, clinical and biochemical parameters were detectable (data not shown).

Discussion {#s4}
==========

In this study investigating TTR values in blood and CSF of LBD patients, CSF TTR levels were significantly higher in this cohort of patients compared to controls. The effect was mainly driven by non-demented LBD patients, explaining, as a diagnosis, approximately 7 percent of the variation in the CSF TTR levels. This makes it tempting to speculate that Asyn pathology alone (PDND patients rarely have marked additional brain pathology such as leucoaraiosis [@pone.0048042-Bohnen1], [@pone.0048042-Bohnen2] and Abeta~1--42~ pathology [@pone.0048042-Maetzler1], [@pone.0048042-Han1], [@pone.0048042-Shirahama1]) induces expression of central TTR. This observation may be explained by the known occurrence of oxidative stress in LBD [@pone.0048042-Maetzler5], [@pone.0048042-VicenteMiranda1], as CSF TTR values have been observed to rise in response to oxidative stress [@pone.0048042-Li1]. In addition, an involvement of TTR in inflammatory processes - a common feature observed in brains of patients suffering from LBD - has also been suggested [@pone.0048042-Santos1]. In the light of previous reports which mainly found *decreased* CSF TTR levels in disorders that are not primarily associated with inflammation (i.e., depression [@pone.0048042-Hatterer1], AD [@pone.0048042-Li1], [@pone.0048042-Gloeckner1] and amyotrophic lateral sclerosis [@pone.0048042-Ryberg1]), but *increased* levels in disorders typically associated with inflammatory processes (such as Guillain Barré syndrome and chronic inflammatory demyelinating polyneuropathy [@pone.0048042-Tumani1]--[@pone.0048042-Chiang1]) it may be interesting to focus in future studies on putative interaction pathways between inflammation and TTR in Asyn-associated pathology.

Actually it is not entirely clear whether (misfolded) Asyn is a target protein of TTR. The latter mainly functions as a transport protein, and is able to transfer e.g. Abeta~1--42~, as a misfolded peptide, from the neuron to the CSF [@pone.0048042-Serot1]. A recent study also showed that Abeta~1--42~-stressed neurons increase the expression of TTR [@pone.0048042-Buxbaum1]. Thus it is intriguing to hypothesize that Asyn is also a target protein of TTR, and TTR may have an influence on Asyn-associated pathology. Indeed, indirect evidence for this suggestion comes from a recent study investigating levels of monomeric and oligomeric Asyn in saliva using MALDI-TOFTOF MSMS ion search and Western blotting [@pone.0048042-Guerreiro1]. In this study, symptomatic individuals with a heterozygous V30M mutation in *TTR* had much more intense Asyn-positive bands and a higher number of such bands at higher molecular mass (indicative of oligomeric forms of Asyn) than had control individuals and, most interestingly, *TTR* mutation carriers who underwent orthotropic liver transplantation. This strongly indicates that TTR is associated with clearance of (misfolded) Asyn.

Interestingly, demented LBD patients had relatively low CSF TTR levels, comparable to controls [@pone.0048042-Riisoen1]. This is exciting in the light of recent studies demonstrating decreased CSF TTR levels in AD patients [@pone.0048042-Li1], [@pone.0048042-Gloeckner1], and the regular occurrence of Abeta~1--42~ pathology in demented LBD patients. Together with the observation that PDND patients have increased CSF TTR levels one may hypothesize that demented LBD patients face two driving forces with regard to TTR-associated pathways: Asyn pathology which goes along with increased TTR expression, and Abeta~1--42~ pathology associated with decreased TTR expression. Based on the abovementioned associations between TTR levels and amyloid pathology, one can also hypothesize that increased TTR levels in the brain protect against Abeta~1--42~ pathology. Indeed, there is accumulating evidence from *in-vitro* and *in-vivo* studies that TTR has beneficial direct and indirect effects on Abeta-associated pathology (reviewed in [@pone.0048042-Li1]).

Serum TTR levels were not significantly different between LBD patients and controls. Post-hoc analyses demonstrated slightly reduced TTR levels in demented compared to non-demented LBD patients. Although results did not survive correction for multiple testing, they may motivate to future, hypothesis-driven studies focusing on this particular aspect as decreased serum TTR levels have already been described in AD patients [@pone.0048042-Velayudhan1], [@pone.0048042-Han1], [@pone.0048042-Elovaara1],, and are regarded as a biochemical marker for malnutrition [@pone.0048042-Serot1], [@pone.0048042-Carriere1] and inflammation [@pone.0048042-MyronJohnson1].

We found weak but significant negative correlations between CSF TTR levels and the three actually best-established neurodegenerative markers in CSF, i.e. Abeta~1--42~, total tau and phospho-tau. Together with the observed lack of such an association between peripheral TTR and these neurodegenerative markers, the observations may point to a specific interaction of central TTR with LBD-associated amyloid clearance. Higher CSF TTR levels were observed in non-demented LBD patients who regularly show relatively low CSF tau levels [@pone.0048042-Mollenhauer1], [@pone.0048042-Shi1]. This argues for an interaction of TTR with the specific neurodegenerative process (total tau) and axonal pathology (phospho-tau). The negative correlation between TTR and Abeta~1--42~ CSF levels is somehow counterintuitive and more difficult to explain as, in individuals with Abeta~1--42~ pathology, CSF Abeta~1--42~ is regularly low and tau parameters are high. Under physiological conditions, CSF TTR binds Abeta~1--42~ and keeps it soluble especially in CSF [@pone.0048042-Serot1]. Decreased CSF TTR values may indicate that this dynamic equilibrium is affected, leading to accumulation and aggregation of Abeta~1--42~ proteins, amyloid formation, and neurotoxicity [@pone.0048042-Schwarzman1].

Analysis of SNPs that have been shown to influence binding capacity of TTR to amyloid did not add relevant information in this study. This may be due to sample size, but also to the fact that rather the absolute quantity of TTR than its function may be associated with LBD pathophysiology. Interestingly, we also did not find a significant association between demographic and clinical parameters (except the above reported, diagnosis of LBD and occurrence of dementia), and TTR values. This may indicate that TTR, although obviously involved in amyloidogenic and clearance pathways in LBD, cannot serve as a marker of disease progression and severity.

In conclusion, data presented in this study argue for a role of TTR in both Asyn- and Abeta~1--42~-associated LBD pathologies. The obvious interaction of centrally produced TTR with pathophysiological mechanisms in these neurodegenerative processes should motivate to more in-depth analyses.

Supporting Information {#s5}
======================
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Post-hoc analyses of transthyretin levels between different groups

(DOC)
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Click here for additional data file.
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